GlassScriptPhysician profile
Iman Imanirad
NPI 1790872653
$11,849.23
in general payments reported to CMS, 2019-2025
16 companies · $9,360 in 2025
The $9,360 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2022: $22.06 · 2023: $2,156 · 2024: $89.76 · 2025: $9,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,128 · Food and Beverage: $1,426 · Travel and Lodging: $964 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,127.50 |
| Food and Beverage | $1,425.65 |
| Travel and Lodging | $963.71 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $8,346.90 | 2025 | |
| Eisai INC. | $2,040.83 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $252.06 | 2019-2025 | Onivyde |
| Intera Oncology, INC | $214.83 | 2025 | Intera |
| Roche Products Limited | $211.00 | 2025 | |
| Array Biopharma INC | $195.82 | 2022-2025 | Braftovi, Tukysa, Mektovi |
| Boston Scientific Corporation | $135.75 | 2025 | General - Interventional Oncology |
| Pfizer INC. | $124.99 | 2025 | |
| Lilly USA, LLC | $117.23 | 2025 | Retevmo |
| Seagen INC. | $89.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.69 | 2023 | |
| Btg International INC. | $24.28 | 2024 | |
| Aimmune Therapeutics, INC. | $18.85 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iman Imanirad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.